Cargando…

855. Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis: A Real-World Evidence Analysis in the United States

BACKGROUND: Persistence to preexposure prophylaxis (PrEP) is an important determinant of its efficacy, but evidence on real-world persistence is lacking. This study assesses adherence to F/TDF and F/TAF for PrEP both in terms of discontinuation and re-initiation patterns. METHODS: We identified HIV-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Li, Shvachko, Valentina, Das, Moupali, Carter, Christoph C, Baeten, Jared, Magnuson, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644189/ http://dx.doi.org/10.1093/ofid/ofab466.1050

Ejemplares similares

103. Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence
por: Tao, Li, et al.
Publicado: (2020)

995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline
por: Campbell, Thomas, et al.
Publicado: (2020)

1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial
por: Wohl, David, et al.
Publicado: (2019)

1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial
por: Mills, Anthony, et al.
Publicado: (2019)

866. Adherence to F/TDF for PrEP in Dried Blood Spots and HIV Infection Rates: A Pooled Analysis of Global PrEP Studies
por: Liu, Albert, et al.
Publicado: (2021)

1556. Increase in New HIV Diagnoses Following Decrease in Use of Pre-Exposure Prophylaxis (PrEP) During the COVID-19 Pandemic
por: Tao, Li, et al.
Publicado: (2023)

999. Using the F/TDF Adherence-Efficacy Relationship to Calculate Background HIV incidence: Results from the DISCOVER trial
por: Glidden, David V, et al.
Publicado: (2020)

337. Switching from TDF to TAF: Missed Opportunities for Statin Use in HIV
por: Mallon, Patrick, et al.
Publicado: (2019)

69. Incidence of metabolic complications among treatment-naïve adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks
por: Daar, Eric, et al.
Publicado: (2021)

Weight gain before and after switch from TDF to TAF in a U.S. cohort study
por: Mallon, Patrick WG, et al.
Publicado: (2021)

Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides
por: Mallon, Patrick W G, et al.
Publicado: (2021)

Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
por: Thimm, Matthew A., et al.
Publicado: (2022)

EXM 85.5
Publicado: (1985)

2087. Prescription Adherence and Persistence on Oral Pre-exposure Prophylaxis (PrEP) Among PrEP-Naive (PN) Individuals After F/TAF Approval in the United States (US)
por: Elion, Rick A, et al.
Publicado: (2022)

318. Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) in Hispanic/Latinx and Black Participants: Efficacy, Bone and Renal Safety Results from a Pooled Analysis of 7 Clinical Trials
por: DeJesus, Edwin, et al.
Publicado: (2019)

2088. Real-World Geographic Variations of HIV Diagnosis Rates among Individuals Prescribed and not Prescribed Oral HIV Pre-Exposure Prophylaxis (PrEP) Regimens in the United States
por: Tao, Li, et al.
Publicado: (2022)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
por: Squillace, Nicola, et al.
Publicado: (2020)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation
por: Bukkems, Laura H., et al.
Publicado: (2023)

A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination
por: Sax, Paul E, et al.
Publicado: (2017)

Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction—A Prospective Cohort Study
por: Surial, Bernard, et al.
Publicado: (2020)

979. BMI and ASCVD Risk Score Changes in Virologically Suppressed Patients with HIV Switching from TDF to TAF Containing ART
por: Schafer, Jason J, et al.
Publicado: (2019)

828. Short- and Long-Term Metabolic Changes in Virologically Suppressed Patients Switching from TDF to TAF Containing Antiretroviral Therapy
por: Schafer, Jason J, et al.
Publicado: (2021)

Changes in bone quality after switching from a TDF to a TAF based ART: A pilot randomized study
por: Soldado-Folgado, Jade, et al.
Publicado: (2023)

Ocular and periocular tumors in 855 Asian Indian geriatric patients
por: Kaliki, Swathi, et al.
Publicado: (2021)

LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
por: Sax, Paul, et al.
Publicado: (2020)

Estimation of new HIV diagnosis rates among high‐risk, PrEP‐eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States
por: Mera, Robertino, et al.
Publicado: (2019)

Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)
por: Cespedes, Michelle, et al.
Publicado: (2022)

Improvement in Hydriding and Dehydriding Features of Mg–TaF(5)–VCl(3) Alloy by Adding Ni and x wt% MgH(2) (x = 1, 5, and 10) Together with TaF(5) and VCl(3)
por: Kwak, Young-Jun, et al.
Publicado: (2021)

Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis
por: Huang, Xiaojie, et al.
Publicado: (2018)

Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)
por: Johnson, Leah M., et al.
Publicado: (2019)

Taf2 mediates DNA binding of Taf14
por: Klein, Brianna J., et al.
Publicado: (2022)

No Emergent Resistance in HIV-1 Infected Virologically-Suppressed Subjects Who Switched to R/F/TAF
por: Porter, Danielle, et al.
Publicado: (2017)

Pressure-Induced Superconductivity of the Quasi-One-Dimensional Organic Conductor (TMTTF)(2)TaF(6)
por: Itoi, Miho, et al.
Publicado: (2022)

A Randomized Clinical Trial of Transgender Women Switching to B/F/TAF: The (mo)BETTA Trial
por: Lake, Jordan E, et al.
Publicado: (2023)

Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW)
por: Defechereux, Patricia A., et al.
Publicado: (2015)

1611. Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced People With HIV and a History of Antiretroviral Drug Resistance Mutations
por: Trottier, Benoit, et al.
Publicado: (2023)

Correction to Lancet Child Adolesc Health 2019; 3: 855–70
Publicado: (2019)

1012. Efficacy, safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected virologically-suppressed older adults in a real-world setting
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2020)

853. Real-World Persistency of Patients Receiving Tenofovir-Based Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the US
por: Oglesby, Alan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cnmj0jf6q7in5bbruv92d9dvsu